Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Shockwave Medical, Inc. (SWAV)
|
Add to portfolio |
|
|
|
| Price: |
$187.41
| | Metrics |
| OS: |
36.8
|
M
| |
40
|
% ROE
|
| Market cap: |
$6.89
|
B
| |
54
|
% ROIC
|
|
Net cash:
|
$234
|
M
| |
$6.38
|
per share
|
|
EV:
|
$6.65
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$157
|
M
| |
42.5
|
x EV/EBITDA
|
|
EBIT
|
$149
|
M
| |
44.5
|
x EV/EBIT
|
| EPS |
$6.43
| |
29.2
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 489.7 | 237.1 | 67.8 | 42.9 | 12.3 | 1.7 |
| Revenue growth | 106.5% | 249.8% | 57.9% | 250.1% | 613.4% | |
| Cost of goods sold | 65.0 | 41.4 | 21.0 | 17.2 | 7.3 | 2.8 |
| Gross profit | 424.7 | 195.7 | 46.8 | 25.8 | 5.0 | -1.1 |
| Gross margin | 86.7% | 82.5% | 69.0% | 60.0% | 40.9% | -65.0% |
| Sales and marketing | 162.0 | 111.3 | 51.7 | 30.6 | 17.5 | 6.4 |
| Research and development | 81.7 | 50.5 | 36.9 | 32.9 | 22.7 | 18.0 |
| General and administrative | 56.9 | 34.7 | 23.9 | 14.1 | 6.0 | 5.4 |
| EBIT | 121.7 | -7.2 | -65.7 | -51.8 | -41.2 | -30.8 |
| EBIT margin | 24.8% | -3.0% | -96.9% | -120.8% | -336.0% | -1793.7% |
| Pre-tax income | 120.8 | -8.8 | -65.6 | -51.0 | -41.1 | -30.6 |
| Income taxes | -95.2 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 |
| Net income | 216.0 | -9.1 | -65.7 | -51.1 | -41.1 | -30.6 |
| Net margin | 44.1% | -3.9% | -96.9% | -119.1% | -335.2% | -1781.0% |
| |
| Diluted EPS | $5.70 | ($0.26) | ($1.99) | ($2.14) | ($23.39) | ($19.71) |
| Shares outstanding (diluted) | 37.9 | 35.1 | 33.1 | 23.9 | 1.8 | 1.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|